Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Register Now Saturday, June 1st, 2024 6:30 – 8:00 PM ET The Westin Boston Seaport District 425 Summer Street Boston, Massachusetts 02210 Hybrid Patients with…
Published online: August 9, 2023 Published online: February 8, 2023 Published online: July 4, 2023 The IF image shows a mitotic keratinocyte with NuMA, a…
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
In this feature Dermatology Week video, Dr Peter Lio discusses what his session, “Alternative and Complementary Dermatology: Educating Patients,” will cover during the meeting.
Review Dermatology Times’ coverage of Rosacea Awareness Month.
Perspectives in Alopecia Areata May 2024
Thursday, May 9, 2024 | 11:30 am – 12:00 pm ET What are the early signs and symptoms of Alzheimer’s disease? When should we be…
Dermatology Times is looking back on the top stories in dermatology from the month of April.
This consensus statement develops an international definition and diagnostic criteria for generalized pustular psoriasis using the modified Delphi model.
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.